NC-4016 is under clinical development by NanoCarrier and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect NC-4016’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their NC-4016 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
NC-4016 (oxaliplatin, Debio 0507/DACH-Platin Micelle ), a new generation DACH platin cytotoxic nanoparticular compound is under development for the treatment of solid tumour, lymphoma, and primitive hepatocarcinoma. It is administered intravenously. The drug candidate consists of micellar nanoparticles utilizing micellar nanoparticle technology. DACH-platin is an active metabolite of oxaliplatin.
NanoCarrier is a drug development company that develops and produces pharmaceuticals using micellar nanoparticles technology. The company’s pipeline products include NC-6004, VB-111, ENT103, NC-6004, NC-6300, NC-6100, TUG1 and RUNX1. NanoCarrier’s NC-6004 is used for the treatment for pancreatic cancer, head and neck cancer, bladder cancer, and biliary tract cancer. The company’s VB-111 is used for the treatment of recurrent glioblastoma, ovarian cancer and thyroid cancer. Its micellar nanoparticle technology is also used in developing cosmetics and healthcare products. The company operates its laboratory in Kanagawa, Japan. NanoCarrier is headquartered in Tokyo, Japan.
Quick View NC-4016 LOA Data
|Highest Development Stage|